47 results
424B3
COYA
Coya Therapeutics Inc
24 Jun 24
Prospectus supplement
5:31pm
not generate sufficient revenue to achieve or maintain profitability.
The audit report with respect to our financial statements contains a paragraph
8-K
EX-10.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
(i) Material … of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange
424B3
ip503
16 Jan 24
Prospectus supplement
4:06pm
S-3
tw485pqj1tnrk6yysn
4 Jan 24
Shelf registration
4:46pm
8-K
EX-10.1
los9qh
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
3no1w9
21 Aug 23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya’s Board of Directors
5:01pm